Valuation : Revance Therapeutics, Inc.

Market Cap 319M 275M 258M 236M 443M 30.41B 445M 3.06B 1.19B 15.38B 1.2B 1.17B 51.04B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 469M 440M 402M 755M 51.82B 759M 5.21B 2.04B 26.21B 2.04B 2B 86.97B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
18.57
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-80.27% 383M
-1.67%-3.93%+35.31%-4.35% 80.65B
-0.90%+0.65%-20.11%-34.58% 59.9B
-3.35%+3.50%+449.76%+23.28% 57B
-6.78%-5.59%-5.25%+27.67% 53.35B
-2.43%-0.64%+7.60%+165.06% 49.29B
-1.35%+1.94%+60.24%-17.37% 32.73B
-2.64%-2.24%+46.59%+94.75% 25.89B
-0.09%+6.23%+18.13%+218.05% 23.9B
-0.34%+1.04%+59.33%+110.57% 17.07B
Average -1.68%+1.41%+65.16%+50.28% 40.02B
Weighted average by Cap. -2.10%+1.01%+79.96%+43.65%

Financials

2022 2023
Net sales 133M 114M 107M 97.95M 184M 12.64B 185M 1.27B 496M 6.39B 498M 487M 21.22B 234M 202M 189M 173M 325M 22.32B 327M 2.25B 876M 11.29B 879M 860M 37.46B
Net income -356M -308M -288M -263M -495M -33.99B -498M -3.42B -1.33B -17.19B -1.34B -1.31B -57.04B -324M -280M -262M -239M -450M -30.9B -453M -3.11B -1.21B -15.63B -1.22B -1.19B -51.85B
Net Debt 77.76M 67.13M 62.93M 57.46M 108M 7.42B 109M 746M 291M 3.75B 292M 286M 12.44B 225M 194M 182M 166M 312M 21.41B 314M 2.15B 841M 10.83B 843M 825M 35.93B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock